Four top US firms have taken prominent roles on consumer goods giant Kimberly-Clark’s multibillion-dollar deal to acquire Kenvue – the former consumer healthcare division of Johnson & Johnson.
The two companies announced today (3 November) that they had reached a deal which values Kenvue – the manufacturer of Tylenol, the painkiller recently linked to autism by US President Donald Trump – at approximately $48.7bn.
Your limit of 1 article in 30 days is up. Please login for full access or subscribe.
Corporate users - click here for simple access (no password needed).
For more information, please contact [email protected]
